Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QL1706 in Advanced Bone and Soft Tissue Sarcoma
NCT06939855Phase 2Recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Sep 2025
- Primary completion
- May 2027
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of QL1706 in bone sarcoma and soft tissue sarcoma (STS), sponsored by Sun Yat-sen University. Primary endpoint: Progression-Free Survival at 12 weeks. Started Sep 2025; status: recruiting.
02
Drugs
QL1706
03
Conditions
bone sarcomasoft tissue sarcoma (STS)
Beyond the preview
Go deeper on NCT06939855.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06939855.